Pharmafile Logo
Pharmafocus logo
Advanced Search

Orkambi

Showing 15 posts of 16 posts found.

vertex-headquarters

Vertex’s cystic fibrosis portfolio to be made available across Northern Ireland and Wales

November 13, 2019
Research and Development, Sales and Marketing Kalydeco, NHS, Orkambi, Symkevi, Vertex, pharma

After drawn out negotiations and much discontent among cystic fibrosis (CF) patients and their advocates, Vertex has announced that a …

News
vertex-headquarters

Scotland turns down Vertex’s Orkambi

August 13, 2019
Manufacturing and Production Orkambi, SMC, Scotland, Vertex, cystic fibrosis, pharma

The Scottish Medicines Consortium (SMC) has turned down Vertex’ cystic fibrosis drug Orkambi on the grounds that it is not …

News
julyaugust_2019_cover

Read the July/August edition of Pharmafocus online now!

June 28, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, Orkambi, Trump, UK, brexit, generics, manufacturing compliance, pharma

The latest monthly edition of Pharmafocus, the July/August issue, is available to read for free online now!The UK remains split …

News
vertex-headquarters

MPs discuss breaking Vertex’s IP rights to bring Orkambi to UK

June 11, 2019
Research and Development Orkambi, Vertex, access, house of commons, pharma, pricing

MPs yesterday discussed circumventing Vertex’s patent on cystic fibrosis medicine Orkambi (Lumacaftor/ivacaftor) as a means of breaking the deadlock and …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

June 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, EMA, Janssen, Orkambi, Pfizer

It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. …

News
vertex-headquarters

Parents of children with cystic fibrosis start Orkambi buyers club

June 5, 2019
Research and Development NHS, Orkambi, Vertex, cystic fibrosis

Parents of children with cystic fibrosis have started an Orkambi buyers’ club to import generic versions of Vertex’s drug from …

News

The price of access: Can the NHS afford Orkambi?

April 29, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing

The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …

Feature
vertex-headquarters

Vertex destroyed nearly 8,000 packs of Orkambi in 2018

March 28, 2019
Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis

Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …

News
vertex-headquarters

Vertex doubles Q4 profits, angering cystic fibrosis drug advocates in UK

February 11, 2019
Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma

Despite ongoing controversy surrounding the currently stalled negotiations between Vertex and the NHS to make its cystic fibrosis (CF) drug …

News
vertex-headquarters

Vertex’s Orkambi can be used in even younger cystic fibrosis patients, says European Commission

January 22, 2019
Manufacturing and Production, Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma

Vertex has announced that the European Commission has decided to approve a label extension in the region for Orkambi (lumacaftor/ivacaftor) …

News
houses-of-parliament-1055056_960_720

UK Ministers call on Vertex to speed up price negotiations

April 23, 2018
Sales and Marketing NHS, NICE, Orkambi, UK government, Vertex, biotech, drugs, pharma, pharmaceutical

After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …

News
shutterstock_87495637

Orkambi deemed not suitable for NHS use

July 27, 2016
Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis

The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …

News

Final Nice appraisal says no to cystic fibrosis drug, Orkambi

June 17, 2016
Medical Communications NICE, Orkambi, Vertex Pharma, cystic fibrosis, recommendation, regulation

The National Institute for Health and Care Excellence (Nice) has issued a final appraisal determination rejecting cystic fibrosis drug, Orkambi …

News

Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco

May 10, 2016
Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation

The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX).  SMC did not recommend …

News
nice

NICE draft guidance says ‘no’ to cystic fibrosis drug Orkambi

March 23, 2016
Research and Development, Sales and Marketing NICE, Orkambi, Vertex, cystic fibrosis

NICE has issued draft guidance not recommending Vertex’s Orkambi (lumacaftor/ivacaftor) for use on the National Health Service (NHS) in England …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024